These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38186347)

  • 1. Acute myeloid leukemia-driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias.
    Fowler-Shorten DJ; Maynard RS; Hampton K; Altera A; Markham M; Ehikioya M; Wojtowicz EE; Bowles KM; Rushworth SA; Hellmich C
    Haematologica; 2024 May; 109(5):1576-1581. PubMed ID: 38186347
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we selectively target AML stem cells?
    Jordan CT
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
    Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
    Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospects for Venetoclax in Myelodysplastic Syndromes.
    Garcia JS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
    Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
    Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
    [No Abstract]   [Full Text] [Related]  

  • 9. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
    Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
    Aldoss I; Marcucci G
    Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
    [No Abstract]   [Full Text] [Related]  

  • 12. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
    Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
    Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
    Roy T; An JB; Doucette K; Chappell AM; Vesole DH
    Leuk Lymphoma; 2022 Mar; 63(3):759-761. PubMed ID: 35076333
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].
    Wang X; Bao XB; Zhang J; Song BQ; Li MY; Xie JD; Shen HJ; Wu DP; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):691-694. PubMed ID: 36709157
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Nachmias B; Aumann S; Haran A; Schimmer AD
    Br J Haematol; 2024 Apr; 204(4):1146-1158. PubMed ID: 38296617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of Bcl-2 inhibitor venetoclax in acute myeloid leukemia].
    Zhang Y; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):438-440. PubMed ID: 34218592
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 19. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.